As M&A Deals Rise, Can Biotech Pharma Break Loose?

After a relatively sluggish 2024 for mergers & acquisitions (M&A) activity in the biopharma sector, the environment could be more conducive for deals in the rest of 2025. The industry, like the rest of the capital markets, will be keeping an eye on interest rates as monetary easing by the U.S. Federal Reserve could open the door for cheaper financing and thus, potentially more M&A in biopharma.

“Interest rates play a significant role in M&A because most deals are financed using a combination of debt and equity,” a USC law article on the effect of interest rates on M&A noted. It added that in a high interest rate environment, the “increase in the cost of debt and the additional lending requirements placed on debtors make taking on debt significantly more expensive and time-consuming, which can cool the appetite of businesses looking to merge or acquire.”

Hopefully, this can reverse with the Fed implementing rate cuts, but the question remains: How aggressive will they be? The biopharma industry will be eagerly watching.

In the meantime, the biotech and pharma industries could be offering value to traders looking for sectors outside of tech poised to move higher.

“It’s the widest discount to the S&P 500 biotech has seen in three decades,” said Robert Moffat of Middlefield Funds. “Investors are circling back, and we see ample room for further outperformance as autumn sets in.”

Strength in both the biotech and pharma sectors is also evident in their respective S&P select industry indexes. Both have rebounded past their pre-Liberation Day sell-off levels.

^SPBIOSI data by YCharts

2 Trade Options for a Biopharma Resurgence

If the biotech industry can continue its rally, traders may want to take a closer look at the Direxion Daily S&P Biotech Bull 3x Shares (LABU), which tracks the S&P Biotechnology Select Industry Index (SPSIBITR). That modified equal-weighted index measures the performance of the biotechnology sub-industry, which mitigates concentration risk if traders were to handpick names individually in the sector.

Likewise, if the pharmaceuticals industry can continue trending higher, then traders should take a look at the Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). The fund tracks the S&P Pharmaceuticals Select Industry Index (SPSIPHTR), which is also a modified equal-weighted index comprised of constituents within the pharmaceuticals sub-industry.

Both funds offer 3x exposure to their respective indexes, so only experienced traders should use these tactical ETF products.

For more news and information, visit the Leveraged & Inverse Content Hub.

Earn free CE credits and discover new strategies